Profusa develops bioengineered, tissue-integrating biosensors that become one with the body to detect and continuously transmit medical-grade data of body chemistry for personal and medical use. Its first clinical offering, the Profusa Lumee™ Oxygen Platform, is CE Marked for use in the European Union and is designed to report reliable tissue oxygen levels both acutely and long-term. Potential applications cited include monitoring compromised tissue such as peripheral artery disease, chronic wounds like diabetic ulcers and pressure sores, sleep apnea, COPD, and reconstructive surgery. The company intends to use the Series C proceeds to advance commercialization of the Lumee Oxygen Platform and to accelerate development of its glucose biosensor technology. Profusa is led by chairman and CEO Ben Hwang, Ph.D. The financing strengthens the company's ability to move toward broader market adoption and further product development. Profusa develops biologically integrated, implanted biosensors for long-term, continuous monitoring of body chemistry to improve personal health and manage disease. Its first product, the Lumee Oxygen Sensing System™, measures tissue-oxygen perfusion and is slated to be available in Europe in early 2016 for clinical management of chronic wounds. The company intends to use recent funding to advance development and commercialization of its technology. Profusa is led by chairman and CEO Ben Hwang, Ph.D., and was founded in 2009 in South San Francisco, CA. In conjunction with the Series B, Karen Liu of 3E Bioventures and Joan Braddi of Google joined Profusa’s board. To date the company has raised more than $30M in funding.

Total raised

$58M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2018